Asa Henin

Cooley advised Insys Therapeutics on its initial public offering. Insys Therapeutics, now trading on the Nasdaq Stock Market under the symbol "INSY," is an Arizona-based commercial-stage specialty pharmaceutical company. Insys develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products.

Synthorx, a developer of protein therapeutics, in its $63 million Series C financing.

Cooley advised HTG Molecular Diagnostics on its initial public offering. HTG is a commercial stage company that develops and markets a novel technology platform to facilitate the routine use of complex molecular profiling. The company trades on the Nasdaq Global Market under the symbol "HTGM."

San Diego – Cooley represented Websense in its approximately $1 billion acquisition by Vista Equity Partners. Websense is a global leader in protecting organizations from the latest cyber attacks and data theft, and Vista is a leading private equity firm focused on investments in software, data and technology-enabled businesses.

Under the terms of the agreement, Websense will become a privately held company. Its senior management is expected to continue working with the San Diego-based company.

Cooley advised Allogene Therapeutics, Inc. on its $372.6 million initial public offering of 20,700,000 shares of common stock. The underwriters have a 30-day option to purchase an additional 2,700,000 shares. Partners Charles Bair and Charlie Kim led the Cooley team advising Allogene Therapeutics.

Goldman Sachs, J.P. Morgan Securities, Cowen and Jefferies acted as joint book-running managers for the offering.

Allogene Therapeutics is a clinical stage immuno-oncology company developing allogeneic T cell therapies for the treatment of cancer. The company’s shares now trade on the Nasdaq Global Select Market under the symbol “ALLO.”